TY - JOUR
T1 - New Technologies in Clinical Trials in Corneal Diseases and Limbal Stem Cell Deficiency
T2 - Review from the European Vision Institute Special Interest Focus Group Meeting
AU - Schlereth, Simona L.
AU - Hos, Deniz
AU - Matthaei, Mario
AU - Hamrah, Pedram
AU - Schmetterer, Leopold
AU - O'leary, Olivia
AU - Ullmer, Christoph
AU - Horstmann, Jens
AU - Bock, Felix
AU - Wacker, Katrin
AU - Schröder, Hannes
AU - Notara, Maria
AU - Haagdorens, Michel
AU - Nuijts, Rudy M.M.A.
AU - Dunker, Suryan L.
AU - Dickman, Mor M.
AU - Fauser, Sascha
AU - Scholl, Hendrik P.N.
AU - Wheeler-Schilling, Thomas
AU - Cursiefen, Claus
N1 - Publisher Copyright:
© 2020 S. Karger AG, Basel. Copyright: All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - To discuss and evaluate new technologies for a better diagnosis of corneal diseases and limbal stem cell deficiency, the outcomes of a consensus process within the European Vision Institute (and of a workshop at the University of Cologne) are outlined. Various technologies are presented and analyzed for their potential clinical use also in defining new end points in clinical trials. The disease areas which are discussed comprise dry eye and ocular surface inflammation, imaging, and corneal neovascularization and corneal grafting/stem cell and cell transplantation. The unmet needs in the abovementioned disease areas are discussed, and realistically achievable new technologies for better diagnosis and use in clinical trials are outlined. To sum up, it can be said that there are several new technologies that can improve current diagnostics in the field of ophthalmology in the near future and will have impact on clinical trial end point design.
AB - To discuss and evaluate new technologies for a better diagnosis of corneal diseases and limbal stem cell deficiency, the outcomes of a consensus process within the European Vision Institute (and of a workshop at the University of Cologne) are outlined. Various technologies are presented and analyzed for their potential clinical use also in defining new end points in clinical trials. The disease areas which are discussed comprise dry eye and ocular surface inflammation, imaging, and corneal neovascularization and corneal grafting/stem cell and cell transplantation. The unmet needs in the abovementioned disease areas are discussed, and realistically achievable new technologies for better diagnosis and use in clinical trials are outlined. To sum up, it can be said that there are several new technologies that can improve current diagnostics in the field of ophthalmology in the near future and will have impact on clinical trial end point design.
KW - Anterior segment OCT
KW - Confocal laser scanning microscopy
KW - Cornea
KW - Diagnostic
KW - Dry eye disease
KW - End points
KW - European vision institute
KW - Fuchs endothelial dystrophy
KW - Graft versus host disease
KW - Limbal stem cell deficiency
KW - New technologies
UR - http://www.scopus.com/inward/record.url?scp=85095846490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095846490&partnerID=8YFLogxK
U2 - 10.1159/000509954
DO - 10.1159/000509954
M3 - Review article
C2 - 32634808
AN - SCOPUS:85095846490
SN - 0030-3747
VL - 64
SP - 145
EP - 167
JO - Ophthalmic Research
JF - Ophthalmic Research
IS - 2
ER -